ArticlePloS one2026
Clinical and metabolic profile of adults with obesity attending lifestyle medicine clinics.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLifestyle Medicine Clinics (LMCs) in primary care provide structured, multidisciplinary obesity care, but evidence from Saudi Arabia on patient profiles and the effectiveness of pharmacologic therapy in this setting is limited.
methodsWe conducted a retrospective cohort study at a primary health care center in Prince Sultan Military Medical City, Riyadh (2023-2024). Adults aged 18-75 years with Body Mass Index (BMI) 30-40 kg/m² and at least one obesity-related comorbidity were included. Patients received either Liraglutide plus lifestyle modification or lifestyle modification alone. Data from the LMCs electronic registry were analyzed after 1:1 propensity score matching. Within-group changes were evaluated using paired tests; between-group differences over time were analyzed using repeated-measures ANOVA.
resultsAmong 664 patients (299 receiving Liraglutide and 365 receiving lifestyle modification alone), 280 matched pairs were analyzed (median age 40 years; 73% female). Both groups achieved significant within-group reductions in BMI, systolic and diastolic blood pressure, and HbA1c (all p < 0.05). Between-group comparisons showed a statistically significant difference only in waist circumference change (p = 0.03). Mean BMI change was - 0.75 kg/m² with Liraglutide versus - 0.71 kg/m² without Liraglutide (p = 0.939). No significant between-group differences were observed for glycemic control, blood pressure, or lipid parameters.
conclusionsIn a real-world primary care setting, Liraglutide plus lifestyle modification and lifestyle modification alone both produced a substantial benefit in metabolic and anthropometric parameters. The incremental benefit of Liraglutide was confined to a modest reduction in waist circumference and did not translate into clinically meaningful differences compared with lifestyle intervention alone. Structured, multidisciplinary lifestyle care should remain the foundation of obesity management, with pharmacotherapy targeted to selected patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.